New evidence and developments regarding the management of blood glucose levels, antiplatelet therapy, and erectile dysfunction prompted this update of the 2009 guidance. There were safety concerns surrounding some blood glucose lowering medicines, new evidence on new dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, new indications and combinations for licensed drugs, and the potential impact of drugs coming off patent on health and economic issues. New evidence and safety issues relating to the off label use of antiplatelet therapy (aspirin and clopidogrel) in the primary prevention of cardiovascular disease were also considered.
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Type 2 diabetes affects 6% of the UK population 1 and is commonly associated with obesity, physical inactivity, raised blood pressure, and disturbed blood lipid levels. It causes long term microvascular and macrovascular complications, plus reduced quality of life and life expectancy. The management of diabetes is complex and needs to address the prevention of cardiovascular disease and microvascular disease and the detection and management of early vascular complications.
This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE), 2 recently updated due to the availability of new evidence and developments. The article also summarises a selection of recommendations which still stand. • See linked infographic for offering treatment beyond these drugs in response to changes in HbA 1c .
Recommendations
• The GDG concluded that the Medicines and Healthcare products Regulatory Agency (MHRA) guidance and patient suitability should be considered for pioglitazone. Pioglitazone is associated with an increased risk of heart failure, bladder cancer, and bone fracture. Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment. The MRHA advises that prescribers should review individuals after 3-6 months of treatment, and continue treatment only if benefit is seen.
• The GDG noted there was limited information on the long term safety of DPP-4 inhibitors but considered the evidence was strong enough to recommend these as treatment options if both other drugs were contraindicated or not tolerated, but again the MHRA guidance should be considered.
• When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: 
Management of selected related risks and symptoms
The role of phosphodiesterase-5 inhibitors for erectile dysfunction in men with type 2 diabetes has been changed and it is now a weaker recommendation (see below) because of concerns about the quality of the evidence and the lack of comparative data versus testosterone.
• Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.
[
new 2015, based on low quality evidence and the experience and opinion of the GDG]
After reviewing the role of aspirin in the primary prevention of cardiovascular disease in adults with type 2 diabetes, the GDG decided that neither aspirin nor clopidogrel should be offered for adults with type 2 diabetes without cardiovascular disease.
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How patients helped create this guidance
The GDG included lay members who helped formulate the recommendations summarised here.
Guidelines into practice
• Has everyone with a diagnosis of diabetes in the last year been offered a structured education programme?
• Have you offered lifestyle advice, including diet and physical activity, to the person with type 2 diabetes at this visit?
• Have you considered whether standard HbA 1c targets should apply for those with comorbidities, frailty, or advanced age?
Further information on the guidance

Methods
This guidance was developed by the Internal Clinical Guidelines team using current NICE guideline methodology (www.nice.org.uk/ guidelinesmanual). The guidance review process involved literature searches to identify relevant evidence, and critically appraising the quality of the evidence identified. Health economic modelling was used to inform disease on the pharmacological management of glycaemic control. A multidisciplinary team of service users, carers, and healthcare professionals (including diabetologists, general practitioners, pharmacists, nurse specialists, and patient and carer representatives) was established-the Guideline Development Group (GDG)-to review the evidence and develop the subsequent recommendations. The guidance then went through an external consultation with stakeholders. The GDG considered the stakeholders' comments, reanalysed the data where necessary, and modified the guidance as appropriate.
NICE has produced three different versions of the guidance: a full version; a summary version known as the "NICE guidance"; and a version for people using NHS services, their families and carers, and the public (www.nice.org.uk/guidance/NG28/ifp/chapter/about-this-information). All these versions are available from the NICE website (www.nice.org.uk/guidance/ng28). Further updates of the guidance will be produced as part of NICE's guideline development programme. Tools to help implement the guidance are available at www.nice.org.uk/guidance/ng28/ resources.
When will this guideline be updated?
NICE is currently considering setting up a standing update committee for diabetes, which would enable more rapid update of discrete areas of the diabetes guidelines, as and when new and relevant evidence is published.
Future research
Based on its review of evidence, the GDG has recommended the following research to improve care:
• How does stopping and switching drug treatments affect levels of blood glucose levels, and what criteria should inform the decision?
• For people who cannot take metformin, what drug combinations are most effective when initial non-metformin monotherapy fails to control blood glucose levels?
• When a third intensification of treatment is indicated, which therapies should be used to control blood glucose?
• What are the long term complications and effects on blood glucose control with drugs such as dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors and meglitinides?
• In adults for whom self monitoring of blood glucose is appropriate, what is the optimal frequency for self monitoring?
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